1-5 of 5
Pei-Jer Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti–Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model

Wei-Tien Tai, Chung-Wai Shiau, Yong-Shi Li, Yao-Li Chen, Pei-Yi Chu, Jui-Wen Huang, Cheng-Yi Hsu, Yi-Chieh Hsu, Pei-Jer Chen, Kuen-Feng Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (1): 27–36.
https://doi.org/10.1158/1535-7163.MCT-13-0595
Published: 13 January 2014
View article titled, SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti–Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model
Open the PDF for SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti–Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model in another window
Includes: Supplementary data
Journal Articles

Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3

Wei-Tien Tai, Ann-Lii Cheng, Chung-Wai Shiau, Chun-Yu Liu, Ching-Huai Ko, Mai-Wei Lin, Pei-Jer Chen, Kuen-Feng Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 452–463.
https://doi.org/10.1158/1535-7163.MCT-11-0412
Published: 08 February 2012
View article titled, Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3
Open the PDF for Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3 in another window
Journal Articles

Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A

Kuen-Feng Chen, Hui-Chuan Yu, Chun-Yu Liu, Hui-Ju Chen, Yi-Ching Chen, Duen-Ren Hou, Pei-Jer Chen, Ann-Lii Cheng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (5): 892–901.
https://doi.org/10.1158/1535-7163.MCT-10-0794
Published: 08 May 2011
View article titled, Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A
Open the PDF for Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A in another window
Journal Articles

Abstract A105: Phase 2 trials of linifanib (ABT‐869) in advanced hepatocellular, renal cell and non‐small cell lung cancer: Associations of response by CT or DCE‐MRI with patient outcome

Han Chong Toh, Wei Peng Yong, Yu‐Ning Wong, Eng‐Huat tan, Christian K. Kollmannsberger, Viswanath Devanarayan, Ke Zhang, Yanping Luo, Daniel Chen, Edward Ashton, Justin L. Ricker, Dawn Carlson, Pei‐Jer Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A105.
https://doi.org/10.1158/1535-7163.TARG-09-A105
Published: 10 December 2009
View article titled, Abstract A105: Phase 2 trials of linifanib (ABT‐869) in advanced hepatocellular, renal cell and non‐small cell lung cancer: Associations of response by CT or DCE‐MRI with patient outcome
Journal Articles

Abstract A155: Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Kuen‐Feng Chen, Wen‐Chi Feng, Chih‐Hung Hsu, Pei‐Jer Chen, Ann‐Lii Cheng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A155.
https://doi.org/10.1158/1535-7163.TARG-09-A155
Published: 10 December 2009
View article titled, Abstract A155: Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells